These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34766870)

  • 1. Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?
    Ansari Z; Pawar S; Seetharaman R
    Postgrad Med; 2022 Mar; 134(2):187-199. PubMed ID: 34766870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytokine model of schizophrenia: emerging therapeutic strategies.
    Girgis RR; Kumar SS; Brown AS
    Biol Psychiatry; 2014 Feb; 75(4):292-299. PubMed ID: 24439555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case.
    Huang LC; Soysal E; Zheng W; Zhao Z; Xu H; Sun J
    BMC Syst Biol; 2015; 9 Suppl 4(Suppl 4):S2. PubMed ID: 26100720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery.
    Xu R; Wang Q
    J Biomed Inform; 2015 Aug; 56():348-55. PubMed ID: 26151312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative and nitrosative stress biomarkers in chronic schizophrenia.
    Boll KM; Noto C; Bonifácio KL; Bortolasci CC; Gadelha A; Bressan RA; Barbosa DS; Maes M; Moreira EG
    Psychiatry Res; 2017 Jul; 253():43-48. PubMed ID: 28346888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiome and adaptive immunity in schizophrenia.
    Agorastos A; Bozikas VP
    Psychiatriki; 2019; 30(3):189-192. PubMed ID: 31685450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of oxidative stress by histamine H₃ receptor-ligands in experimental models of schizophrenia.
    Mahmood D; Khanam R; Pillai KK; Akhtar M
    Arzneimittelforschung; 2012 May; 62(5):222-9. PubMed ID: 22331799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection in Schizophrenia and Its Therapeutic Implications.
    Kim YK; Na KS
    Psychiatry Investig; 2017 Jul; 14(4):383-391. PubMed ID: 28845163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural compounds for oxidative stress and neuroprotection in schizophrenia: composition, mechanisms, and therapeutic potential.
    Khan AN; Jawarkar RD; Zaki MEA; Al Mutairi AA
    Nutr Neurosci; 2024 Nov; 27(11):1306-1320. PubMed ID: 38462971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease comorbidity-guided drug repositioning: a case study in schizophrenia.
    Wang Q; Xu R
    AMIA Annu Symp Proc; 2018; 2018():1300-1309. PubMed ID: 30815174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oxidative stress involvement in schizophrenia pathophysiology: a review].
    Fendri C; Mechri A; Khiari G; Othman A; Kerkeni A; Gaha L
    Encephale; 2006; 32(2 Pt 1):244-52. PubMed ID: 16910626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of oxidative stress markers in schizophrenia.
    Zhang M; Zhao Z; He L; Wan C
    Sci China Life Sci; 2010 Jan; 53(1):112-124. PubMed ID: 20596963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
    Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The serotonin transporter gene 5-HTTLPR polymorphism is associated with affective psychoses but not with schizophrenia: A large-scale study in the Russian population.
    Golimbet V; Korovaitseva G; Lezheiko T; Abramova LI; Kaleda VG
    J Affect Disord; 2017 Jan; 208():604-609. PubMed ID: 28029428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between trace elements in serum from bipolar disorder and schizophrenia patients considering treatment effects.
    Santa Cruz EC; Madrid KC; Arruda MAZ; Sussulini A
    J Trace Elem Med Biol; 2020 May; 59():126467. PubMed ID: 31954929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress-mediated particulate matter affects the risk of relapse in schizophrenia patients: Air purification intervention-based panel study.
    Wei Q; Ji Y; Gao H; Yi W; Pan R; Cheng J; He Y; Tang C; Liu X; Song S; Song J; Su H
    Environ Pollut; 2022 Jan; 292(Pt B):118348. PubMed ID: 34637828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation in schizophrenia: A question of balance.
    Leza JC; García-Bueno B; Bioque M; Arango C; Parellada M; Do K; O'Donnell P; Bernardo M
    Neurosci Biobehav Rev; 2015 Aug; 55():612-26. PubMed ID: 26092265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study.
    Mamakou V; Hackinger S; Zengini E; Tsompanaki E; Marouli E; Serafetinidis I; Prins B; Karabela A; Glezou E; Southam L; Rayner NW; Kuchenbaecker K; Lamnissou K; Kontaxakis V; Dedoussis G; Gonidakis F; Thanopoulou A; Tentolouris N; Zeggini E
    BMC Psychiatry; 2018 Aug; 18(1):249. PubMed ID: 30071838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neuroimmunology of schizophrenia.
    Smyth AM; Lawrie SM
    Clin Psychopharmacol Neurosci; 2013 Dec; 11(3):107-17. PubMed ID: 24465246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study.
    ; Amare AT; Schubert KO; Hou L; Clark SR; Papiol S; Heilbronner U; Degenhardt F; Tekola-Ayele F; Hsu YH; Shekhtman T; Adli M; Akula N; Akiyama K; Ardau R; Arias B; Aubry JM; Backlund L; Bhattacharjee AK; Bellivier F; Benabarre A; Bengesser S; Biernacka JM; Birner A; Brichant-Petitjean C; Cervantes P; Chen HC; Chillotti C; Cichon S; Cruceanu C; Czerski PM; Dalkner N; Dayer A; Del Zompo M; DePaulo JR; Étain B; Falkai P; Forstner AJ; Frisen L; Frye MA; Fullerton JM; Gard S; Garnham JS; Goes FS; Grigoroiu-Serbanescu M; Grof P; Hashimoto R; Hauser J; Herms S; Hoffmann P; Hofmann A; Jamain S; Jiménez E; Kahn JP; Kassem L; Kuo PH; Kato T; Kelsoe J; Kittel-Schneider S; Kliwicki S; König B; Kusumi I; Laje G; Landén M; Lavebratt C; Leboyer M; Leckband SG; Tortorella A; Manchia M; Martinsson L; McCarthy MJ; McElroy S; Colom F; Mitjans M; Mondimore FM; Monteleone P; Nievergelt CM; Nöthen MM; Novák T; O'Donovan C; Ozaki N; Ösby U; Pfennig A; Potash JB; Reif A; Reininghaus E; Rouleau GA; Rybakowski JK; Schalling M; Schofield PR; Schweizer BW; Severino G; Shilling PD; Shimoda K; Simhandl C; Slaney CM; Squassina A; Stamm T; Stopkova P; Maj M; Turecki G; Vieta E; Volkert J; Witt S; Wright A; Zandi PP; Mitchell PB; Bauer M; Alda M; Rietschel M; McMahon FJ; Schulze TG; Baune BT
    JAMA Psychiatry; 2018 Jan; 75(1):65-74. PubMed ID: 29121268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.